

Specifications

Feature	UBREATH® BA200
Product Name	UBREATH® Breath Gas Test System
Model	BA200
Detection Principle	Advanced Electrochemical Sensor
Measurement Range	NO: 0 - 4000 ppb
Low Detection Limit	1.0 ppb
Accuracy (NO)	≤ 50 ppb: ±2.5 ppb > 50 ppb: ±5.0%
Repeatability (NO)	≤ 50 ppb: SD < 1.5 ppb > 50 ppb: CV < 3.0%
Analysis Time	≤ 40 seconds
Exhalation Time	Standard Mode / Pediatric Mode
Display	10.1-inch IPS Touchscreen
Operating Environment	5°C ~ 35°C, RH ≤ 80% (non-condensing)
Power Input	DC 5V / 2A

Distributore esclusivo per Italia



IOIAMEO S.R.L.
Telefono: +39.375.84.30.520
e-mail: info@ioiameo.it
Sede operativa: Via Risorgimento, 12
20076 Mediglia(MI)-ITALIA
www.ioiameo.it

With a presence in over 50 countries, UBREATH is your trusted global partner in respiratory care—backed by 20+ patented innovations and a comprehensive product portfolio, delivering high-quality diagnostics and enabling sustainable growth beyond devices.



e-LinkCare Meditech Co.,Ltd.
No.9 Tongjiang Road, Baita District, Xianju Economic Development Zone,
317317, Taizhou, Zhejiang, People's Republic of China
Email: info@e-linkcare.com



Youtube




www.e-linkcare.com

UBREATH®

Breath Gas Test System

Model BA200



- + High Sensitivity & Precision
- + Result within 40s
- + Real-time Signal Curves
- + Triple-Check Mode



ISO 13485:2016



CE Marked
(IVDD)



IVDR Transition
in Progress



Asthma Management



Chronic Cough Evaluation



COPD Overlap (ACO)



Eosinophilic Airway
Inflammation

Product Features

The U BREATH® Breath Gas Test System (Model BA200)

is a non-invasive, point-of-care device for assessing airway inflammation in patients with respiratory conditions such as asthma.

It measures fractional exhaled nitric oxide (FeNO) or nasal nitric oxide (nNO), providing clinicians with a biomarker of inflammation to support diagnosis and disease management.


Analysis of Exhaled Nitric Oxide



Index: **FeNO, CaNO**

Assess Type 2 Inflammation in large and small airways to aid asthma diagnosis, guide corticosteroid therapy, and predict biologic responses.

Analysis of Nasal Nitric Oxide




Index: **FnNO**

Evaluates upper airway inflammation, with clinical applications in the assessment of allergic rhinitis, primary ciliary dyskinesia, and other related conditions.

Hardware Highlights


Maximized Patient Safety



- Dual-Defense System: A unidirectional handle and high-efficiency filters physically isolate airflow, significantly preventing cross-contamination.

★ China Invention Patent – ZL 202010346890.7

Reliable Result



- Electrochemical sensor with proprietary low-noise technology for high sensitivity and precision.
- Detection limit as low as 1.0 ppb.

★ U.S. Patent Application No. 18/040,720
★ China Invention Patent – ZL 202210052659.6
★ PCT Patent No. WO2021259328


Software Highlights

Multi-parameter Measurement




- Available for FeNO, CaNO, FnNO.
- Support joint-measurement models.

Quick Mode for GPs



- Accelerates initial patient intake for immediate testing readiness.
- Designed for efficient, high-volume testing.

Multi-dimensional Quality Control



- Real-time monitoring of expiratory flowrate and mouth pressure for quality control.
- Real-time display of test result curves for quality control.
- ATS/ERS-compliant averaging of reproducible measurements ensures reliable results.

Pediatric Friendly UI



- Boost First-Try Success.
- Engaging "Airplane" and "Balloon" animation guides, combined with age-specific breathing profiles, simplify testing for pediatric patients.

Zero Drift Calibration



- Each test includes a built-in zero-gas measurement to eliminate zero drift—ensuring accurate and reliable FeNO results.

Seamless IT Integration



- Connected Workflow.
- Centralized patient data management, network folder sharing, and direct printing.